Top life sciences deals of 2025 show where capital is moving
VERSION 2 — FULL ANALYSIS
A year-end PharmaShots ranking, built with DealForma data, offers a snapshot of where life sciences capital went in 2025: toward big-ticket licensing, oncology, platform technologies, and de-risked assets with either late-stage data or commercial traction. The report’s top three deals were GSK and Jiangsu Hengrui Pharma at roughly $12.5 billion, Takeda and Innovent Biologics at roughly $11.4 billion, and BioNTech and Bristol Myers Squibb at roughly $11.1 billion, reflecting a year in which large companies leaned heavily on partnerships to refill pipelines and broaden modality exposure. (linkedin.com)
That ranking lands against a broader recovery in sector dealmaking. DealForma’s 2025 review says global healthcare and life sciences M&A reached 585 transactions with $269.3 billion in announced value, nearly doubling 2024 levels. The firm says value creation was concentrated in biopharma, diagnostics, and data-driven services, while the market favored scaled, commercially advanced, and lower-risk assets. Nature also reported that 2025 biopharma dealmaking was energized by a run of notable M&A and licensing activity, with DealForma data showing especially strong volume in the first half of the year. (dealforma.com)
The PharmaShots list suggests that platform access mattered as much as any single molecule. Its summary says big pharma pursued bispecific antibodies, siRNA therapeutics, AI-driven drug discovery, and gene-editing capabilities, signaling a shift toward “innovation engines” rather than one-off asset purchases. That framing shows up clearly in the top-ranked GSK-Hengrui collaboration, announced on July 28, 2025, which gave GSK rights outside Greater China to HRS-9821, a PDE3/4 inhibitor in development for COPD, and set up work on as many as 11 additional programs across respiratory, immunology and inflammation, and oncology. GSK said the deal included a $500 million upfront payment, with the potential total value reaching about $12 billion in success-based milestone payments, plus tiered royalties; PharmaShots rounded the deal to about $12.5 billion. (gsk.com)
The next two deals reinforce the same pattern. Takeda said on October 21, 2025 that it had entered a license and collaboration agreement with Innovent for two late-stage oncology medicines, IBI363 and IBI343, outside Greater China. PharmaShots valued that partnership at about $11.4 billion. Earlier in the year, on June 2, 2025, BioNTech and Bristol Myers Squibb announced a global strategic partnership for BNT327, a next-generation bispecific antibody candidate for multiple solid tumor types. BMS said the agreement included a $1.5 billion upfront payment, $2 billion in non-contingent anniversary payments through 2028, and up to $7.6 billion in additional development, regulatory, and commercial milestones, which aligns with the roughly $11.1 billion headline valuation cited by PharmaShots. (takeda.com)
Lower on the list, the report also captures how broad the definition of a “life sciences deal” became in 2025. Examples include Shionogi’s approximately $2.5 billion purchase of Tanabe’s RADICAVA business, giving Shionogi a commercial ALS asset and rare disease infrastructure, and a Datavault AI-Scilex agreement valued at about $2.56 billion around blockchain-enabled biotech data monetization. Another notable entry is Fosun Pharma’s collaboration with Clavis Bio, which PharmaShots said could reach $7.25 billion across up to 20 programs. Those transactions point to a market where commercial products, research platforms, and data infrastructure were all being valued as strategic growth levers. (linkedin.com)
The same themes show up outside the deal table. In a separate PharmaShots roundup of the Top 20 Healthcare IPOs of 2025, the publication said public investors continued to back biotech, medtech, digital health, and AI-enabled healthcare companies, with the strongest interest going to scaled platforms, precision medicine, advanced diagnostics, and revenue-generating healthcare businesses. The IPO market was led by Medline Industries at $7.2 billion, followed by Caris Life Sciences at $494 million and Lumexa Imaging at $462.5 million. PharmaShots also highlighted a visible shift toward AI-driven drug discovery, precision medicine, digital care platforms, oncology, and metabolic therapies. In other words, the capital markets story broadly matched the partnering story: investors were still willing to fund healthcare innovation, but they appeared to prefer businesses with platform breadth, technology integration, or clearer commercial pathways.
Large private pools of capital were active too. PharmaShots reported that Blackstone closed Blackstone Life Sciences VI at its $6.3 billion hard cap, making it the largest life sciences vehicle of its kind and about 40% larger than its predecessor. Blackstone said its life sciences platform, launched in 2018, had about $15 billion in assets under management as of Q4 2025 and had committed roughly $2 billion over the prior 12 months through partnerships with companies including Merck, Teva, Alnylam, and Novartis. That matters because it adds another layer to the 2025 financing picture: not just strategic licensing and M&A, but also deep institutional capital backing drug development, medtech, and royalty-based transactions.
Private equity interest in established specialty pharma was also part of the backdrop. PharmaShots noted that CVC Capital Partners proposed a roughly €10.9 billion acquisition of Recordati, valuing the company at €52 per share and aiming to take it private, subject to due diligence and financing. Recordati is relevant here because it had already expanded in rare disease through its 2021 acquisition of EUSA Pharma for about $845 million, strengthening its rare cancer portfolio. That proposed transaction fits the same broader pattern seen across 2025: buyers and investors were willing to pay for companies with durable specialty franchises, rare-disease exposure, and commercially proven assets.
Industry commentary around the year’s deal flow has emphasized many of the same themes. Nature reported that 2025’s momentum was driven in part by major M&A and licensing activity, while DealForma’s own reviews describe a market that rewarded late-stage, approved, and platform-based assets. Inference: when capital becomes more selective, companies tend to pay up for assets that can either generate revenue sooner or support multiple shots on goal across a pipeline. That helps explain why oncology, respiratory disease, immunology, rare disease, diagnostics, AI-enabled tools, and enabling technologies featured so prominently in the year’s biggest transactions and financings. (nature.com)
Why it matters: For veterinary professionals, this is mostly a business and innovation signal rather than a practice-management story. Still, it matters because human biopharma capital often sets the pace for adjacent technology development, manufacturing capacity, diagnostics infrastructure, and partnership structures that can later influence animal health. Areas like biologics production, precision oncology, AI-enabled discovery, advanced imaging, surgical robotics, and specialty commercialization don’t stay neatly separated forever. When large pharma companies, IPO investors, and private-capital funds spend aggressively on scalable platforms and advanced therapeutics, veterinary medicine may eventually benefit through technology transfer, companion diagnostics, contract manufacturing availability, or renewed investor interest in translational animal health plays. (dealforma.com)
What to watch: The next question is whether 2025 was a rebound year or the start of a longer cycle. If 2026 brings continued appetite for cross-border licensing, late-stage oncology, respiratory assets, AI-enabled healthcare, precision diagnostics, and platform technologies, veterinary stakeholders should watch for more spillover into diagnostics, biologics manufacturing, AI tools, and specialty therapeutics that could affect both industry strategy and future care options for pet parents. It is also worth watching whether large dedicated funds and private-equity buyers keep leaning into specialty and rare-disease businesses, because that would further support the idea that healthcare capital is consolidating around scalable platforms and commercially durable niches rather than purely speculative early-stage bets.